Prosta-Qs patent - pending blend of active ingredients have been clinically shown to address the symptoms associated with Chronic Non-bacterial Prostatitis as well as improve overall prostate health.
Prosta-Q was tested in a randomized placebo controlled clinical trial by the Institute of Male Urology (IMU) and was led by Dr. Daniel Shoskes, M.D. At the time of the study, Dr. Shoskes was a staff urologist at the UCLA Medical Center. The study showed that 82% of males taking Prosta-Q had an "improvement of symptoms from Non-Bacterial Chronic Stage III Prostatitis".
These results were published in the American Medical Journal of Urology. Prosta-Q is also cited as a primary method for addressing the symptoms associated with Chronic Non-bacterial Stage IIIa Prostatitis in various authoritative resources and books including "The Textbook on Prostatitis" and "The Prostatitis Manual", both edited by the noted prostatitis expert, Dr. J Curtis Nickel of Queens University in Canada.
The Prosta-Q complex is a proprietary combination of clinically proven ingredients including Quercetin, a bioflavonoid with anti-inflammatory and antioxidant effects, Saw Palmetto, Cranberry, Bromelain and Papain, to aid digestion, as well as zinc. Prosta-Q has been shown to be the most effective bioflavonoid formulation yet tested to "provide significant symptomatic improvement"1 in men with Chronic Non-Bacterial Prostatitis /Chronic Pelvic Pain Syndrome.
Prosta-Q was born out of the intense desire to tailor a combination of the most potent of the bioflavonoid supplements with a mixture of other naturally occurring compounds needed to overcome absorption issues while at the same time promoting and maintaining a healthy prostate to successfully address symptoms associated with:
Chronic nonbacterial prostatitis or inflammatory chronic pelvic pain syndrome is the inflammation of the prostate not due to bacterial infection. It refers to a condition affecting patients who present symptoms of prostatitis without a positive result after urine culture or expressed prostate secretion (EPS) culture. Currently, the National Institute of Health refers to Chronic Non-Bacterial Prostatitis as Category IIIa Prostatitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).
Nonbacterial prostatitis is typically a chronic, painful disease. The symptoms characteristically go away and then come back without warning. The urine and fluid from the prostate show no evidence of a known infecting organism, but the semen and other fluids from the prostate contain cells that the body usually produces to fight infection.
Treatment with antibiotics and drugs that relax the muscles of the prostate gland is often tried and commonly fails. It is the least understood type of prostatitis and hardest to treat. This form of prostatitis is the most common. It is believed to occur eight times more often than bacterial prostatitis. It occurs in association with other diseases such as Reiter syndrome (arthritis, conjunctivitis [eye inflammation] and inflammation of the genital and urinary systems).
Chronic Pelvic Pain Syndrome (Category III Prostatitis):
Chronic pelvic pain syndrome (CPPS) occurs just in men. It is a persistent discomfort or pain that you feel in your lower pelvic region - mainly at the base of your penis and around your anus. The source of the pain is thought to be the prostate gland. The prostate gland is only found in men. It lies just beneath the bladder. It is normally about the size of a chestnut. The urethra, a tube that passes urine from the bladder, runs through the middle of the prostate. The prostate helps to make semen. However, most semen is made by the seminal vesicle. Currently, the National Institute of Health refers to Chronic Pelvic Pain Syndrome as Category IIIa Prostatitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS).
Chronic pelvic pain syndrome is another name for Chronic nonbacterial prostatitis (or close medical condition association). The noninflammatory chronic pelvic pain syndrome was formerly called prostatodynia.
There are various types of prostatitis, one of which is prostatodynia (or Prostadynia). Sometimes called noninflammatory chronic pelvic pain syndrome, it is the occurrence of prostatitis symptoms, without inflammation or bacterial infection. Currently, the National Institute of Health refers to Prostatodynia as Category IIIb.
Doctors understand very little about why some people - often young, otherwise healthy men - develop this problem. Theories to explain prostatodynia include an abnormal buildup of pressure in the urinary tract, irritation resulting from an autoimmune or chemical process, or pain generated in the nerves and muscles within the pelvis. There may be a link between prostatodynia and increased stress, because this condition is often found in men with "Type A" personalities in high-stress situations.
The main symptom is pain in the pelvis or perineum (the area between the scrotum and the anus.) However, many of the nonbacterial prostatitis symptoms may be present, such as fever, pain in the lower back, pain in genital area, general body aches, burning or pain on urination, increased urinary frequency, urgency, pain or discomfort during or after ejaculation, decreased libido, and occasionally visible blood in the urine.
Sexual Dysfunction :
Do you experience pain before, during or after ejaculation? Are you less interested in having sexual encounters? Do you live with prostate pain, chronic pelvic pain, or rectal pain? Have you confronted penile dysfunction due to pain or are you experiencing an uncomfortable throbbing sensation in your genital or rectal areas? Are you suffering from prostatic congestion? While regular ejaculation and prostatic massage are helpful for some patients many patients with post-ejaculatory pain can exacerbate their symptoms with repeated ejaculations, thereby creating no long-term relief.
20 million men of all ages share the symptoms of non-bacterial chronic prostatitis. While there are several types of prostatitis diagnosed in men, including bacterial prostatitis (acute and chronic), non-bacterial prostatitis and prostatodynia account for 95% of all prostatitis diagnoses. Symptoms can include perineal pain, reduced urine flow and possibly impotence and pain before, during and after ejaculation.
Prostatitis is a term used to describe inflammatory conditions or infections of the prostate gland. It is a very common condition, affecting hundreds of thousands of men, causing millions of doctor's office visits each year. It is thought that most cases of prostatitis result from bacterial infection, but evidence of infection is not always found. An infected or inflamed prostate can cause painful urination and ejaculation, and if left untreated, serious complications.
Prostatitis can affect men of any age and it is estimated that 50% of men experience the disorder during their lifetime. Prostatitis is the most common urological disorder in men over the age of 50 and the third most common disorder in men younger than 50.
Early studies with bioflavonoids for prostatitis treatment were disappointing because of their low and inconsistent absorption rates. Dr. Shoskes, in association with his colleagues, recognized this and structured a formula specifically designed to increase bioavailability.
The results of the research in Chronic Non-Bacterial Prostatitis patients using Prosta-Q have been dramatic and compelling in significantly and rapidly addressing the symptoms associated with Category III Prostatitis (Chronic Pelvic Pain Syndrome).
Other studies suggest that bioflavonoid intake can be linked to "protection against coronary heart disease" and a "reduction of the increased capacity for signal transduction in human cancer cells".
Prosta Q contains:
No Artificial flavor
OBJECTIVES: The National Institutes of Health (NIH) category III chronic prostatitis syndromes (nonbacterial chronic prostatitis and prostatodynia) are common disorders with few effective therapies. Bioflavonoids have recently been shown in an open-label study to improve the symptoms of these disorders in a significant proportion of men. The aim of this study was to confirm these findings in a prospective randomized, double-blind, placebo-controlled trial. METHODS: Thirty men with category IIIa and IIIb chronic pelvic pain syndrome were randomized in a double-blind fashion to receive either placebo or the bioflavonoid quercetin 500 mg twice daily for 1 month. The NIH chronic prostatitis symptom score was used to grade symptoms and the quality-of-life impact at the start and conclusion of the study. In a follow-up unblind, open-label study, 17 additional men received 1 month of a supplement containing quercetin, as well as bromelain and papain (Prosta-O), which enhance bioflavonoid absorption.
RESULTS: Two patients in the placebo group refused to complete the study because of worsening symptoms, leaving 13 placebo and 15 bioflavonoid patients for evaluation in the blind study. Both the quercetin and placebo groups were similar in age, symptom duration, and initial symptom score. Patients taking placebo had a mean improvement in NIH symptom score from 20.2 to 18.8 (not significant), while those taking the bioflavonoid had a mean improvement from 21.0 to 13.1 (P = 0.003). Twenty percent of patients taking placebo and 67% of patients taking the bioflavonoid had an improvement of symptoms of at least 25%. In the 17 patients who received Prosta-Q in the open-label study, 82% had at least a 25% improvement in symptom score.
CONCLUSIONS: Therapy with the bioflavonoid quercetin is well tolerated and provides significant symptomatic improvement in most men with chronic pelvic pain syndrome.